Journal Your Way to Better Health – Why Journaling Benefits Cancer Patients!
Journal your way to better health. Keeping a journal is a great way to help you during your fight against GIST. Read more about the benefits and types of journaling.
DOG1 Gene and GIST – What is the Relationship?
Jonathan Fletcher and Sebastian Bauer of the LRG’s Research Team were among the authors in a study to be published in Cancer Research that examined the relationship between GIST and the expression of the gene DOG1.
Personalized Medicine – Another Look
The issue of personalized medicine, also referred to as "precision medicine" in the article, was addressed in a newsletter article by LRG Executive Director Norman Scherzer in February. We hope to follow up with more articles on the topic soon.
It Will Take Not One Hero but Many: Collaborating for a Cure
Time magazine this month published an in-depth look at how collaboration is beginning to change the way cancer research is approached, citing numerous examples of the effectiveness of scientists working together to find a cure.
New Blood Test Technology May Impact GIST Treatment
A new blood test technology may lead to major changes in treatment of Gastrointestinal Stromal Tumors. Keep reading for more information.
The LRG Responds To Recent Patent Protection Rulings
Following recent coverage on patent protection rulings in India, Life Raft Group Executive Director, Norman Scherzer comments on what this might mean for cancer patients worldwide.
Research Team Meets in New Jersey
The LRG research team meets four times a year, with at least one in-person meeting per year. This year, the team held its in-person meeting at the LRG office in New Jersey March 22-24, 2013.
Who’s laughing now? Actress Mo Collins uses humor in her battle with GIST
Mo Collins is not your typical actress/comedienne, because Mo Collins is a GIST survivor. Keep reading to learn more about Mo Collins and her fight against GIST. Mo is using this gift in a very selfless way by organizing a comedy fundraiser for the Life Raft Group and GIST research.
Stivarga becomes first FDA-approved third-line drug treatment for GIST
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
Family planning with GIST can be a hard decision
Family planning can be one of the hardest decisions patients with GIST make, but for Carolina Ponce Williams the decision was easy. At high risk for progression, Carolina longed to start a family. So she decided to adopt.